Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment
Study Details
Study Description
Brief Summary
This clinical trial program was established according to the ethical principles of the Helsinki declaration and the GCP guiding principle, and a randomized grouping method was used to evaluate the efficacy and safety of Compound Methyl Salicylate Liniment in the treatment of acute and chronic soft tissue pain with a positive control drug, named Diclofenac Sodium Liniment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study is a randomized, double-blind, parallel controlled multicenter clinical trial for evaluate the efficacy and safety of Compound Methyl Salicylate Liniment in the treatment of acute and chronic soft tissue pain with a positive control drug, named Diclofenac Sodium Liniment. A total of 216 participants with acute or chronic tissue pain participated in this clinical trial. The clinical trial cases were equally allocated to each research center, and each center had 30-35 cases. The proportion of patients with acute soft tissue pain and chronic soft tissue pain was 1:1, and the proportion of the experimental group and the control group was 1:1.The observation index include self pain scale record, tenderness scale and swelling, the evaluation period was 7 days.
The statistical analysis plan is prepared by the unit responsible for the statistics, and is prepared before the formal analysis of the data, and is discussed and identified at the blind audit meeting with the major researchers. Statistical analysis will use SAS8.2 statistical analysis software for data processing, and other statistical analysis plan to make detailed provisions. All the statistical tests were two-sided, and the value of P was less than or equal to 0.05, which would be considered statistically significant. Measurement data use case number, mean, standard deviation, minimum, maximum, median and four sub spacing description, counting data and grade data use case number, percentage description.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: experimental group Treated with Compound Methyl Salicylate Liniment group |
Drug: Compound Methyl Salicylate Liniment
Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
|
| Active Comparator: Control group Treated with Diclofenac Sodium Liniment group |
Drug: Diclofenac Sodium Liniment
Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
|
Outcome Measures
Primary Outcome Measures
- Main observation index [7 days]
Self pain scale record (VAS). A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.Operationally a VAS is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end, the patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks, the amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain.
Secondary Outcome Measures
- Secondary observation index [7 days]
Record of tenderness scale(VAS), Swelling. A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. Operationally a VAS is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end, the patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks, the amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with various causes of acute and chronic soft tissue
-
Local symptoms and signs include pain, swelling, bruising, tenderness, joint dysfunction; X-ray showed no fracture, dislocation, bone tumors and bone metabolism and open injury.
Exclusion Criteria:
-
Patients who do not belong to the scope of drug use
-
Muscle, tendon, ligament and other soft tissue have broken completely
-
Accompanied by skin damage or fracture, joint dislocation, bone tumor and metabolic bone disease local tissue damage
-
Use of other drugs or therapies for the treatment of acute and chronic soft tissue pain after trauma
-
Difficult to evaluate the effectiveness and safety of new drugs
-
Severe hypertension, severe heart and lung dysfunction, severe arrhythmia, liver, kidney, hematopoietic system and other serious primary diseases, mental patients
-
Pregnant women, lactating women
-
Allergic constitution and allergic to the known components of the drug
-
Participated in other clinical trials in the past month
-
Use similar analgesics within a week
-
Other researchers considered inappropriate patients to participate in the trial
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Peking University People's Hospital
Investigators
- Study Director: People's Hospital Peking University, Peking University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PUPH20170999